Skip to main content
SpringerLink
Log in

Janus-Kinase-Inhibitor Baricitinib bei rheumatoider Arthritis

Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy (RA-BEAM)

Janus kinase inhibitor baricitinib for rheumatoid arthritis

Randomized, double-blind, placebo- and active-controlled, phase 3 study evaluating the efficacy and safety of baricitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy (RA-BEAM)

  • Klinische Studien
  • Published:
Der Internist Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1a-d

Literatur

  1. Lilly Deutschland (2017) Fachinformation: Olumiant 2 mg/4 mg Filmtabletten. https://www.lilly-pharma.de/de/pdf/fachinformation/fachinformation_olumiant.pdf. Zugegriffen: 31. Juli 2017

    Google Scholar 

  2. Taylor PC, Keystone EC, van der Heijde D et al (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Eng J Med 376:652–662

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Innere Medizin, Rheumatologie, Klinische Immunologie, Osteologie, Schlosspark-Klinik, Akademisches Lehrkrankenhaus der Charité – Universitätsmedizin Berlin, Heubnerweg 2, 14059, Berlin, Deutschland

    R. Alten

  2. Lippetal, Deutschland

    S. Nitschmann

Authors
  1. R. Alten
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Nitschmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Alten.

Ethics declarations

Interessenkonflikt

R. Alten hat Vortragshonorare der Firma Lilly sowie Forschungsunterstützung und Vortragshonorare der Firma Pfizer erhalten. S. Nitschmann gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

M. Hallek, Köln

W. Lehmacher, Köln

N. Marx, Aachen

U. Müller-Ladner, Bad Nauheim

H. Wedemeyer, Hannover

M. Wehling, Mannheim

T.R. Weihrauch, Düsseldorf

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alten, R., Nitschmann, S. Janus-Kinase-Inhibitor Baricitinib bei rheumatoider Arthritis. Internist 58, 1341–1344 (2017). https://doi.org/10.1007/s00108-017-0345-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-017-0345-6

Search

Navigation